Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML

Open source

DOI: 10.1186/s13045-026-01797-4
Published: 2026 Apr 27
Container: Journal of hematology & oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13045-026-01797-4,
  title = {Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.},
  author = {Muñoz J and Locke FL and Reagan PM and Goy A and Jacobson CA and Hill BT and Timmerman JM and Flinn IW and Miklos DB and Pagel JM and Kersten MJ and Forcade E and Topp MS and Houot R and Beitinjaneh A and Zheng D and Chang M and Zhang W and Shen RR and Khalid RD and Kloos I and Wang ML},
  year = {2026},
  journal = {Journal of hematology \& oncology},
  doi = {10.1186/s13045-026-01797-4},
  url = {https://doi.org/10.1186/s13045-026-01797-4}
}

RIS

TY  - JOUR
TI  - Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
AU  - Muñoz J
AU  - Locke FL
AU  - Reagan PM
AU  - Goy A
AU  - Jacobson CA
AU  - Hill BT
AU  - Timmerman JM
AU  - Flinn IW
AU  - Miklos DB
AU  - Pagel JM
AU  - Kersten MJ
AU  - Forcade E
AU  - Topp MS
AU  - Houot R
AU  - Beitinjaneh A
AU  - Zheng D
AU  - Chang M
AU  - Zhang W
AU  - Shen RR
AU  - Khalid RD
AU  - Kloos I
AU  - Wang ML
PY  - 2026
JO  - Journal of hematology & oncology
DO  - 10.1186/s13045-026-01797-4
UR  - https://doi.org/10.1186/s13045-026-01797-4
ER  -

APA

J, M., FL, L., PM, R., A, G., CA, J., BT, H., JM, T., IW, F., DB, M., JM, P., MJ, K., E, F., MS, T., R, H., A, B., D, Z., M, C., W, Z., RR, S., RD, K., I, K., & ML, W. (2026). Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.. Journal of hematology & oncology. https://doi.org/10.1186/s13045-026-01797-4

Source records

pubmed · retrieved 2026-09-27T08:42:04.372Z